Cancer Follow-up: Complete Clinical Guide, Benefits & Recovery

Clinical Overview: Understanding Cancer Follow-up

Cancer Follow-up represents a cornerstone clinical program at Spica Healthcare — Grover Hospital, Bathinda. Supervised directly by Dr. Neha Gupta (Director & Senior Medical Oncologist), this evidence-based pathway integrates sub-millimeter surgical precision, advanced intraoperative 3D navigation, ISO Class-100 Laminar Airflow surgical suites, and personalized accelerated rehabilitation to restore function, eliminate pain, and maximize long-term treatment longevity.

In South-Western Punjab and adjoining regions of Haryana and Rajasthan, patients frequently encounter delayed clinical diagnoses or generalized approaches that fail to address anatomical nuances. At Spica Healthcare, every patient undergoes rigorous digital staging, ensuring that surgical interventions or targeted medical therapies are customized to individual biomechanics and oncological requirements.

Clinical Indications: When is Cancer Follow-up Recommended?

• Cancer patients who have completed curative surgery, chemotherapy, or radiotherapy regimens.

• Routine 3-monthly (Years 1–2), 6-monthly (Years 3–5), and annual (Year 5+) oncological surveillance.

• Cancer survivors experiencing late effects: chronic fatigue, peripheral neuropathy, lymphedema, or joint pain.

• Patients seeking circulating tumor DNA (ctDNA) liquid biopsy testing for peace of mind.

Step-by-Step Surgical & Clinical Pathway at Grover Hospital

Step 1: Comprehensive Survivorship Review

Review of original cancer staging, pathology, treatment history, and physical examination.

Step 2: Biomarker & ctDNA Testing

Targeted blood tumor markers (CEA, CA-125, CA 19-9, PSA) and ctDNA liquid biopsy if indicated.

Step 3: Surveillance Imaging Protocol

NCCN-aligned surveillance imaging (Low-dose CT chest, mammography, ultrasound, or PET-CT).

Step 4: Recurrence Prevention & Wellness Plan

Personalized lifestyle, dietary, and exercise recommendations to prevent cancer recurrence.

Director's Signature Innovation: Comprehensive Cancer Survivorship & Follow-Up Protocol

Dr. Neha Gupta directs the Cancer Survivorship & Follow-Up Clinic at Spica Healthcare. Moving beyond simple clinical checks, every cancer survivor receives a personalized Survivorship Care Plan incorporating ultrasensitive circulating tumor DNA (ctDNA) liquid biopsies for Minimal Residual Disease (MRD) detection — detecting microscopic cancer recurrence months before it can be seen on conventional CT scans — alongside structured surveillance imaging (PET-CT/Mammography), bone density monitoring, and cardiovascular wellness.

✔ ctDNA Minimal Residual Disease (MRD): Ultrasensitive blood testing detecting recurrence months early

✔ Structured Evidence-Based Imaging: NCCN-aligned surveillance intervals preventing over- and under-scanning

✔ Late Effect Management: Dedicated care for lymphedema, chemo-induced neuropathy, and bone loss

✔ Lifestyle & Recurrence Prevention: Evidence-based nutrition, exercise, and metabolic health coaching

Recovery Timeline & Functional Milestones

Phase 1: High-Frequency Surveillance (Years 1–2) (Years 1 – 2)

3-monthly clinical oncology exams, routine blood tumor markers, and 6-monthly surveillance scans (CT/PET-CT).

Phase 2: Intermediate Surveillance (Years 3–5) (Years 3 – 5)

6-monthly oncology checkups, annual mammography / colonoscopy (as indicated), and bone health checks.

Phase 3: Long-Term Survivorship (Year 5+) (Year 5+)

Annual long-term survivorship wellness check, general health optimization, and lifelong remission celebration.

Frequently Asked Clinical Questions (FAQs)

Why are regular cancer follow-up visits critical even after being declared cancer-free?

Cancer follow-up visits are essential to detect any recurrence at the earliest microscopic stage when it is still easily curable, monitor and treat long-term side effects from chemotherapy or surgery, and maintain optimal physical, dietary, and emotional health.

What is ctDNA Minimal Residual Disease (MRD) monitoring?

ctDNA (circulating tumor DNA) testing is a breakthrough 'liquid biopsy' that looks for tiny traces of cancer DNA in your blood. If negative, it gives powerful reassurance of true disease-free remission; if positive, it allows early targeted intervention long before tumors appear on a scan.

Is Cancer Follow-up care covered under Ayushman Bharat?

Yes, post-cancer follow-up consultations, surveillance CT/PET scans, blood tests, and survivorship clinics at Grover Hospital Bathinda are covered under PM-JAY Ayushman Bharat and 30+ private insurance TPAs.

100% Cashless Insurance & PM-JAY Ayushman Bharat Empanelment

At Spica Healthcare — Grover Hospital Bathinda, Cancer Follow-up is fully covered under the Government of India's PM-JAY Ayushman Bharat scheme and over 30+ leading private insurance TPAs. Our on-campus insurance coordinator handles all pre-authorization documentation directly with your insurance company, eliminating financial delays. Families can also share digital DICOM CDs and biopsy reports via WhatsApp (+91 95013 73003) for an urgent surgical review.